← Back to Clinical Trials
Recruiting Phase 2 NCT04566380
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Trial Parameters
Condition Pan-tumor
Sponsor Ono Pharmaceutical Co. Ltd
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 59
Sex ALL
Min Age 16 Years
Max Age N/A
Start Date 2020-09-10
Completion 2026-12-31
Interventions
ONO-4538oxaliplatinS-1
Brief Summary
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Eligibility Criteria
Inclusion Criteria: 1. Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials 2. Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit Exclusion Criteria: 1. Participant judged to be incapable of providing consent for reasons such as concurrent dementia 2. Participant judged by the investigator to be inappropriate as participants of this study